AbbVie is trading 3.05% higher now at $274.83 after Phase 3 EPCORE DLBCL-2 data showed epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone. - Results were announced October 5 and drew further coverage October 7. - Healthcare stocks are stronger while broader markets are lower. - The October 5 guidance trim, reflecting a $216 million R&D charge, is a countervailing factor rather than the clearest explanation for the rise.